USPTO lays ground for review of Fintiv rules

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

USPTO lays ground for review of Fintiv rules

Kathi Vidal
Kathi Vidal

The USPTO's plans to file an Advanced Notice of Proposed Rulemaking related to Fintiv are pending regulatory review

The USPTO has indicated that it plans to initiate regulatory action related to Fintiv, it has emerged.

In a filing with the Office of Information and Regulatory Affairs (OIRA) on Thursday, March 9, the USPTO said it would publish an Advanced Notice of Proposed Rulemaking (ANPRM).

An ANPRM is a preliminary notice that an agency is considering regulatory action. The exact nature of the planned rule changes are unclear but could include draft language of what potential rulemaking will look like and can ask the public what issues it should address.

The OIRA, which reviews draft rules submitted by federal agencies, has 90 days from the date of filing to review requests, although this period can be extended.

The USPTO said its ANPRM would not be economically significant. The OIRA will have to determine whether that’s the case, which is important because agencies must provide more detail if changes are deemed to be economically significant.

Actions are economically significant if they’re likely to have a yearly effect of at least $100 million on the economy, or if the OIRA believes they will materially adversely affect the economy.

If the OIRA doesn’t spot any issues, the USPTO will likely initiate its ANPRM related to Fintiv – the rule introduced in 2020 that compels Patent Trial and Appeal Board judges to discretionarily deny inter partes reviews on the basis that parallel district court cases will finish first.

The office implemented interim guidance in July 2022 addressing Fintiv.

That guidance severely limited when the board could use Fintiv to deny petitions. But the USPTO stated at the time that it would soon explore potential rulemaking on proposed approaches through an ANPRM – which it’s now doing.

News of the ANPRM comes amid a busy time for Fintiv-related matters.

In a judgment yesterday, March 13, the Court of Appeals for the Federal Circuit ruled that tech companies could challenge instructions related to Fintiv because they were issued without notice-and-comment rulemaking.

Notice-and-comment rulemaking requires agencies to issue a Notice of Proposed Rulemaking, but they can issue ANPRMs first to get more information.

If businesses were to prevail on these challenges, the notice-and-comment rulemaking process would be crucial for Fintiv’s survival.

Managing IP will provide further analysis on the Federal Circuit’s ruling in the coming days.


more from across site and SHARED ros bottom lb

More from across our site

Rebekah Gay discusses overcoming self-doubt, supporting the next generation of women lawyers, and how changing client demands are reshaping IP practice
New filing data suggests Germany's grip on UPC litigation remains strong, while Bardehle Pagenberg, Arnold Ruess, Hogan Lovells and Carpmaels notch up notable cases
In 27 years, KASS has expanded to seven countries in southeast Asia and is now eyeing further growth opportunities. Its CEO shares her perspective
Mine Güner discusses bridging law and business, taking the initiative, and why Taylor Swift helped put copyright on the map
Cindy Goh discusses why she launched Cheang & Ariff's IP department, the improving litigation environment in Malaysia and what to consider when using AI
Increased focus on adding patent litigation depth to the firm’s Dallas office was behind the boutique’s most recent hires
IPH's Canadian acquisitions are paying off on paper, but a couple of strong years may not be enough to show that the group's strategy has truly won over the market
Examiner statistics could help patent prosecution practitioners tailor strategies, turning an area of high variability into a potential competitive advantage
The England and Wales High Court’s ruling in Accord v Novartis may not rewrite the law on plausibility, but it does signal a pragmatic approach that could provide greater certainty for life sciences innovators
Firms with established sports relationships and specialised expertise are well positioned to capture the market’s expanded pool of IP work
Gift this article